Hyperparathyroidism Medical Services in China

Hyperparathyroidism is an endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to dysregulated calcium and phosphorus metabolism. It is broadly classified into primary, secondary, and tertiary forms. Primary hyperparathyroidism (PHPT), the most common type, results from autonomous PTH overproduction—typically due to a single parathyroid adenoma (85–90%), less commonly hyperplasia (10–15%), or rarely carcinoma (<1%). Secondary hyperparathyroidism arises as a compensatory response to chronic hypocalcemia, most often driven by chronic kidney disease (CKD) or vitamin D deficiency. Tertiary hyperparathyroidism occurs when long-standing secondary disease leads to irreversible parathyroid gland autonomy, frequently seen in advanced CKD patients post-kidney transplant. Pathophysiologically, elevated PTH increases bone resorption, renal calcium reabsorption, and intestinal calcium absorption (via upregulation of renal 1α-hydroxylase and subsequent calcitriol synthesis), resulting in hypercalcemia, hypophosphatemia, and increased urinary calcium excretion. Epidemiologically, PHPT affects approximately 0.1–0.3% of the general population, with incidence rising sharply after age 50; women are affected two to three times more often than men. Risk factors include prior neck irradiation, genetic syndromes (e.g., MEN1, MEN2A, HRPT2 mutations), lithium therapy, and chronic kidney disease. Untreated or severe cases significantly impair quality of life: patients commonly report debilitating fatigue, cognitive fog, depression, muscle weakness, bone pain, recurrent nephrolithiasis, and gastrointestinal disturbances such as constipation and peptic ulcer disease. Osteoporosis and vertebral fractures increase fracture risk by 2–4 fold; cardiovascular complications—including hypertension, left ventricular hypertrophy, and vascular calcification—are also prevalent. Early diagnosis remains challenging, as up to 80% of newly diagnosed cases in high-resource settings are asymptomatic or minimally symptomatic, identified incidentally via routine serum calcium testing. Delayed management may lead to irreversible renal damage (nephrocalcinosis, chronic kidney disease progression) and skeletal demineralization. Importantly, even mild hypercalcemia correlates with measurable declines in physical functioning, sleep quality, and emotional well-being—underscoring the need for individualized assessment beyond biochemical thresholds alone.

Hyperparathyroidism is a disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to disturbances in calcium, phosphorus, and bone metabolism. It is broadly classified into primary, secondary, and tertiary forms, with primary hyperparathyroidism (PHPT) being the most common endocrine disorder after type 2 diabetes. In PHPT, autonomous PTH overproduction results in hypercalcemia, hypophosphatemia, and increased bone resorption—often asymptomatic but potentially causing nephrolithiasis, osteoporosis, cognitive changes, fatigue, and cardiovascular complications. Management must be individualized based on disease severity, symptomatology, age, comorbidities, and biochemical profile.

Conservative treatment is appropriate for asymptomatic or minimally symptomatic patients meeting strict criteria: serum calcium no more than 1 mg/dL above the upper limit of normal; estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m²; no evidence of nephrocalcinosis, kidney stones, or vertebral fractures on imaging; and bone mineral density (BMD) T-score >−2.5 at lumbar spine, femoral neck, or distal radius. These patients require vigilant monitoring: serum calcium and creatinine every 6 months; annual BMD assessment via dual-energy X-ray absorptiometry (DXA); and periodic 24-hour urinary calcium excretion to assess stone risk. Lifestyle modifications include maintaining adequate hydration (≥2 L/day), restricting sodium intake (<2 g/day), avoiding thiazide diuretics and lithium, and ensuring moderate dietary calcium (1000–1200 mg/day)—neither deficient nor excessive—to prevent secondary hyperparathyroidism or exacerbation of hypercalciuria. Vitamin D repletion is encouraged only if serum 25-hydroxyvitamin D <20 ng/mL, targeting levels between 30–50 ng/mL, as deficiency may worsen PTH elevation without increasing hypercalcemia risk when managed appropriately.

Pharmacologic therapy serves adjunctive or bridging roles. Calcimimetics—specifically cinacalcet—are FDA- and NMPA-approved for PHPT in patients ineligible for surgery or with persistent/recurrent disease postoperatively. Cinacalcet allosterically enhances the calcium-sensing receptor’s sensitivity to extracellular calcium, thereby suppressing PTH secretion and lowering serum calcium. It is titrated starting at 30 mg once daily, up to 180 mg/day, with monitoring of serum calcium and magnesium. Adverse effects include nausea, vomiting, and hypocalcemia (requiring dose adjustment or supplementation). For bone protection, bisphosphonates (e.g., alendronate 70 mg weekly) are indicated in patients with osteoporosis or low BMD, though they do not correct hypercalcemia or reduce PTH. Denosumab, a RANK ligand inhibitor, may be considered in select cases with contraindications to bisphosphonates, but requires careful calcium/vitamin D repletion pre-initiation to avoid severe hypocalcemia. Hormone replacement therapy (HRT) is not recommended solely for hyperparathyroidism management due to unfavorable risk-benefit profiles in most populations.

Surgical intervention remains the only curative treatment for primary hyperparathyroidism. Parathyroidectomy—typically minimally invasive unilateral exploration guided by intraoperative PTH assay (IO-PTH)—achieves cure rates exceeding 95% in experienced centers. Preoperative localization using high-resolution ultrasound and sestamibi (99mTc-MIBI) scintigraphy is standard; 4D-CT and MRI are increasingly utilized for complex or reoperative cases. Intraoperative PTH monitoring confirms successful resection when levels drop ≥50% from baseline at 10 minutes post-excision. Bilateral neck exploration is reserved for multiglandular disease, familial syndromes (e.g., MEN1), or failed prior localization. Complications are rare in high-volume centers: transient hypocalcemia (up to 30%, usually self-limited), permanent hypoparathyroidism (<1%), recurrent laryngeal nerve injury (<0.3%), and hematoma (<0.5%). Surgery is strongly indicated for symptomatic disease, serum calcium >1 mg/dL above normal, creatinine clearance <60 mL/min, renal stones, reduced BMD, age <50 years, or inability to comply with surveillance.

Treatment advantages in China reflect rapid advancements in endocrine surgery, imaging, and multidisciplinary coordination. Major academic hospitals—including Peking Union Medical College Hospital, Shanghai Jiao Tong University Affiliated Ruijin Hospital, and West China Hospital—perform over 1,000 parathyroidectomies annually with standardized protocols endorsed by the Chinese Society of Endocrinology. High-resolution ultrasound is widely accessible and performed by endocrinologists trained in parathyroid mapping, reducing reliance on nuclear medicine. IO-PTH assays are routinely available in tier-3 hospitals, enabling real-time surgical decision-making. Moreover, China’s national health insurance covers cinacalcet and generic bisphosphonates, improving affordability. Telemedicine platforms facilitate longitudinal follow-up, especially for rural patients, while integrated electronic health records support seamless transitions between outpatient endocrinology, nuclear medicine, radiology, and surgery departments.

Post-treatment recovery emphasizes structured, evidence-based guidance. After parathyroidectomy, patients should monitor for perioral numbness, tingling, or muscle cramps—signs of hypocalcemia—and maintain oral calcium (1–2 g elemental calcium daily) and calcitriol (0.25–0.5 mcg/day) for 1–2 weeks, tapering based on serial calcium measurements. Hydration and early ambulation reduce thromboembolic risk. Patients resume normal activities within 3–5 days but avoid heavy lifting (>5 kg) for 10 days. Long-term follow-up includes serum calcium, creatinine, and PTH at 1, 3, 6, and 12 months post-op, then annually. BMD reassessment is recommended at 1–2 years. For medically managed patients, adherence to hydration, dietary sodium restriction, and scheduled monitoring is critical. Psychological support is advised, as fatigue and cognitive complaints often improve gradually over 3–6 months post-surgery. Finally, all patients—regardless of treatment modality—should receive education on recognizing hypercalcemic emergencies (e.g., confusion, polyuria, vomiting) and seeking urgent care. With timely, protocol-driven care, outcomes for hyperparathyroidism in China align closely with international benchmarks, underscoring the value of centralized expertise, technological integration, and patient-centered rehabilitation.